What is CathWorks?
Founded in 2013 and based in Kfar-saba, Israel, CathWorks is at the forefront of medical technology, leveraging artificial intelligence and sophisticated computational science to address the complexities of coronary artery disease. The company's core mission is to improve patient outcomes by providing clinicians with advanced tools that optimize treatment decisions. By analyzing intricate patient data, CathWorks aims to deliver more precise and effective care pathways, reducing the burden of cardiovascular conditions on patients and healthcare systems alike. Their work represents a significant advancement in the application of AI within the critical field of cardiac care.
How much funding has CathWorks raised?
CathWorks has raised a total of $75.8M across 3 funding rounds:
Series B
$15.8M
Series C
$30M
Series D
$30M
Series B (2017): $15.8M with participation from Corundum Open Innovation, Planven Investments, TriVentures, BioStar Capital, Pontifax, and Quark Ventures
Series C (2019): $30M led by Deerfield
Series D (2021): $30M, investors not publicly disclosed
Key Investors in CathWorks
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
Corundum Open Innovation
Corundum Open Innovation is an Israel-Japan venture capital firm focusing on investments in top Israeli high-tech companies and funds, specializing in sectors such as ICT, life sciences, and artificial intelligence.
TriVentures
Triventures is a global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare and other industries, focusing on bio-convergence and data-driven technologies.
What's next for CathWorks?
The recent major strategic investment in CathWorks, following substantial enterprise-level funding, positions the company for accelerated expansion and further technological development. This infusion of capital is expected to fuel advancements in their AI-driven diagnostic and treatment optimization platforms, potentially broadening their market reach and impact. As CathWorks continues to mature, its focus will likely remain on refining its core technology, forging strategic partnerships within the healthcare ecosystem, and scaling its operations to meet the growing global demand for innovative cardiac care solutions. The company's commitment to data-driven insights suggests a future where AI plays an increasingly pivotal role in managing and treating coronary artery disease.
See full CathWorks company page
